PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER Russian patent published in 2016 - IPC C12Q1/68 C12N9/16 C12N15/11 

FIELD: biotechnology.

SUBSTANCE: invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for aggressive hormone-sensitive prostate cancer, where the expression of the marker is increased in comparison with expression in tissue of aggressive hormone-sensitive prostate cancer with the expression in normal tissue or tissue of benign tumour of the prostate, and the use of PDE4D7 as a diagnostic marker for aggressive hormone-sensitive prostate cancer. Also, the present invention relates to a composition for diagnostics, detection, monitoring or prediction of aggressive hormone-sensitive prostate cancer, to a corresponding method of detection, a method which enables to distinguish the benign and aggressive hormone-sensitive prostate cancer, and a method of collecting data as well as to corresponding immunoassays. The present invention also relates to a method of identification of an individual who meets the requirements for aggressive hormone-sensitive prostate cancer, as well as the immunoassay for stratification of an individual with such prostate cancer. In addition, the present invention relates to pharmaceutical compositions and their use for treatment of aggressive hormone-sensitive prostate cancer.

EFFECT: invention enables to diagnose effectively a hormone-sensitive prostate cancer.

32 cl, 19 dwg, 2 tbl, 3 ex